在K562细胞中,CX-5461通过刺激KIF1B的表达来增强意马替尼布诱导的亡
Chaochao Dai1, Xiaopei Cui1, Jie Wang1
1Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Experimental and therapeutic medicine
|February 15, 2024
概括
RNA聚合酶I抑制剂CX-5461增强了伊马替尼的作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 选择性RNA聚合酶I抑制剂CX-5461在白血病疾病中显示出有效性.
- 与CX-5461的组合疗法可能比单一疗法更有效.
- 结合氨酸激酶抑制剂的CX-5461的药理动力学特性需要进一步研究.
研究的目的:
- 为了研究CX-5461对p53-缺乏K562的人类慢性髓性白血病细胞中的imatinib作用的增强.
- 探索潜在的机制,包括素家族成员1B (KIF1B) 基因表达的作用.
主要方法:
- 用CX-5461 (100nM) 和伊马替尼治疗K562细胞.
- 评估细胞活力和细胞亡.
- 对KIF1B基因表达水平的分析.
主要成果:
- 在CX-5461的非细胞毒性度下,K562细胞中强化了imaatinib的前亡效应.
- 调节后的KIF1B基因表达被确定为该组合的亲亡效应的潜在媒介.
- 无论是CX-5461还是单独的伊马替尼布都没有显著影响KIF1B表达.
- 这种组合对KIF1B的调节是特定于细胞类型的,在其他白血病细胞系中并不普遍观察到.
结论:
- 在K562细胞中,CX-5461与伊马蒂尼布协同相互作用,以增强K562细胞的亡.
- 观察到的协同作用可能涉及KIF1B基因表达的上调,以细胞依赖的方式.
- 这种组合对于治疗耐伊马替尼布的慢性髓性白血病具有潜在的临床价值.
关键词:
在CX-5461中使用.的RNA聚合酶I抑制剂.灭症 (apoptosis) 是一种死亡的过程.伊马替尼布 (Imatinib) 的使用情况基因素家族成员1B的基因素.协同效应是一种协同效应.更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K